Origin, Virological Features, Immune Evasion and Intervention of SARS-CoV-2 Omicron Sublineages

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2022 Jul 19

PMID 35853878

Authors

Shuai Xia

Lijue Wang

Yun Zhu

Lu Lu

Shibo Jiang

Affiliations

Soon will be listed here.

Abstract

Recently, a large number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continuously emerged and posed a major threat to global public health. Among them, particularly, Omicron variant (B.1.1.529), first identified in November 2021, carried numerous mutations in its spike protein (S), and then quickly spread around the world. Currently, Omicron variant has expanded into more than one hundred sublineages, such as BA.1, BA.2, BA.2.12.1, BA.4 and BA.5, which have already become the globally dominant variants. Different from other variants of concern (VOCs) of SARS-CoV-2, the Omicron variant and its sublineages exhibit increased transmissibility and immune escape from neutralizing antibodies generated through previous infection or vaccination, and have caused numerous re-infections and breakthrough infections. In this prospective, we have focused on the origin, virological features, immune evasion and intervention of Omicron sublineages, which will benefit the development of next-generation vaccines and therapeutics, including pan-sarbecovirus and universal anti-CoV therapeutics, to combat currently circulating and future emerging Omicron sublineages as well as other SARS-CoV-2 variants.

Citing Articles

Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era.

Cavalli M, Campoli G, Anselmo A, Brandi R, Fortunato A, Di Spirito M Sci Rep. 2025; 15(1):3372.

PMID: 39870695 PMC: 11772649. DOI: 10.1038/s41598-024-84952-6.

Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5.

Dolzhikova I, Tukhvatulin A, Grousova D, Zorkov I, Komyakova M, Ilyukhina A Vaccines (Basel). 2024; 12(10).

PMID: 39460319 PMC: 11512357. DOI: 10.3390/vaccines12101152.

Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.

Jeong H, Rollon R, Kim S, Gil J, Casel M, Jang H Influenza Other Respir Viruses. 2024; 18(10):e70000.

PMID: 39377176 PMC: 11459205. DOI: 10.1111/irv.70000.

Seroprevalence of SARS-CoV-2 infection in pediatric patients in a tertiary care hospital setting.

Pattanakitsakul P, Pongpatipat C, Setthaudom C, Kunakorn M, Sahakijpicharn T, Visudtibhan A PLoS One. 2024; 19(9):e0310860.

PMID: 39316628 PMC: 11421809. DOI: 10.1371/journal.pone.0310860.

Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection.

Holder K, Ings D, Fifield K, Barnes D, Barnable K, Harnum D J Immunol. 2024; 213(8):1105-1114.

PMID: 39248629 PMC: 11457723. DOI: 10.4049/jimmunol.2400250.

References

Clemens S, Weckx L, Clemens R, Mendes A, Ramos Souza A, Silveira M . Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022; 399(10324):521-529. PMC: 8782575. DOI: 10.1016/S0140-6736(22)00094-0. View

Liu Z, Zhou J, Xu W, Deng W, Wang Y, Wang M . A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022; 32(3):269-287. PMC: 8767042. DOI: 10.1038/s41422-022-00612-2. View

Kupferschmidt K . Where did 'weird' Omicron come from?. Science. 2021; 374(6572):1179. DOI: 10.1126/science.acx9738. View

He X, Aid M, Chandrashekar A, Yu J, McMahan K, Wegmann F . A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. Sci Transl Med. 2022; 14(638):eabm4996. PMC: 9802654. DOI: 10.1126/scitranslmed.abm4996. View

Kim S, Kim S, Kim G, Goo J, Kim N, Lee Y . A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. Int J Mol Sci. 2022; 23(11). PMC: 9181758. DOI: 10.3390/ijms23116123. View

Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F . SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022; 7(1):141. PMC: 9047469. DOI: 10.1038/s41392-022-00997-x. View

Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I . Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat Med. 2022; 28(6):1297-1302. DOI: 10.1038/s41591-022-01792-5. View

Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y . SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther. 2021; 6(1):430. PMC: 8678971. DOI: 10.1038/s41392-021-00852-5. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

10.

Oude Munnink B, Sikkema R, Nieuwenhuijse D, Molenaar R, Munger E, Molenkamp R . Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2020; 371(6525):172-177. PMC: 7857398. DOI: 10.1126/science.abe5901. View

11.

Liu Z, Chan J, Zhou J, Wang M, Wang Q, Zhang G . A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res. 2022; 32(5):495-497. PMC: 8866927. DOI: 10.1038/s41422-022-00631-z. View

12.

Huang K, Zhang Y, Hui X, Zhao Y, Gong W, Wang T . Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine. 2021; 67:103381. PMC: 8118724. DOI: 10.1016/j.ebiom.2021.103381. View

13.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

14.

Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M . Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microbes Infect. 2022; 11(1):477-481. PMC: 8820826. DOI: 10.1080/22221751.2022.2030200. View

15.

Su S, Li W, Jiang S . Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern. Trends Immunol. 2022; 43(3):170-172. PMC: 8758279. DOI: 10.1016/j.it.2022.01.009. View

16.

Wei C, Shan K, Wang W, Zhang S, Huan Q, Qian W . Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J Genet Genomics. 2021; 48(12):1111-1121. PMC: 8702434. DOI: 10.1016/j.jgg.2021.12.003. View

17.

Tao K, Tzou P, Kosakovsky Pond S, Ioannidis J, Shafer R . Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Microbiol Spectr. 2022; 10(4):e0092622. PMC: 9430471. DOI: 10.1128/spectrum.00926-22. View

18.

Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J . Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022; 185(12):2103-2115.e19. PMC: 9057982. DOI: 10.1016/j.cell.2022.04.035. View

19.

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View

20.

Elhazmi A, Al-Tawfiq J, Sallam H, Al-Omari A, Alhumaid S, Mady A . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series. Travel Med Infect Dis. 2021; 41:102026. PMC: 7955802. DOI: 10.1016/j.tmaid.2021.102026. View